| Overview |
| bs-2747R-PE |
| Bcr Polyclonal Antibody, PE Conjugated |
| FCM |
| Human, Mouse, Rat |
| Dog, Cow, Horse, Chicken, Rabbit |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Bcr |
| 1201-1271/1271 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 613 |
| Cytoplasm |
| ALL; BCR 1; BCR/ABL FUSION GENE INCLUDED; BCR/FGFR1 FUSION GENE INCLUDED; BCR/PDGFRA FUSION GENE INCLUDED; BCR1; breakpoint cluster region; CML; PHL; BCR_HUMAN. |
| The breakpoint cluster region protein (Bcr) is best know to be involved in genomic translocation with fusion partner Abl (Cbr-Abl) causing chronic myelogenous leukemia (CML). This 160 kDa protein contains a serine/threonine kinase domain, an SH2 binding domain, a GTP/GDP exchange domain and a C-term domain which functions as a GTPase activating protein for p21rac and CDC42. Additionally, Bcr is involved in signal transduction and can down regulate Ras mediated cell signaling. |
| Application Dilution |
| FCM |
1:20-100 |
Powered by Bioz